Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
| ▸ | GUSB | P08236 | 2/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397642 | 0.88 | HRH4 (0.59) | HRH4POLBMAPTKMT2ANOS1 | |
| SCHEMBL27885276 | 0.87 | HRH4 (0.61) | HRH4CYP19A1GUSBPDGFRBPDGFRA | |
| SCHEMBL1260652 | 0.86 | HRH4 (0.60) | HRH4CYP19A1GUSBPDGFRBPDGFRA | |
| SCHEMBL1156515 | 0.86 | HRH4 (0.60) | HRH4CYP19A1GUSBPDGFRBPDGFRA | |
| SCHEMBL12824776 | 0.85 | HRH4 (0.54) | HRH4CYP19A1GUSBPDGFRBPDGFRA | |
| SCHEMBL12862878 | 0.84 | HRH4 (0.62) | HRH4CYP19A1GUSBPDGFRBPDGFRA | |
| SCHEMBL8794605 | 0.84 | HRH4 (0.59) | HRH4CYP19A1GUSBPDGFRBPDGFRA | |
| SCHEMBL28680383 | 0.84 | HRH4 (0.59) | HRH4CYP19A1GUSBPDGFRBPDGFRA | |
| SCHEMBL6245500 | 0.84 | KDM4E (0.57) | HRH4CYP19A1GUSBPDGFRBPDGFRA | |
| SCHEMBL6323164 | 0.81 | HRH4 (0.58) | HRH4CYP19A1GUSBPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111171040-A | Dihydrofuropyran/pyridoindole derivatives and synthesis method thereof | 常州大学 | 2020-05-19 | — | — | CN | disclosed |
| EP-2836494-A1 | NEW ALKYLATING AGENTS | Nerviano Medical Sciences S.r.l. (IT) | 2015-02-18 | — | — | EP | disclosed |
| WO-2013149948-A1 | NEW ALKYLATING AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-10-10 | — | — | WO | disclosed |
| EP-1363925-B8 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | disclosed |
| EP-1776106-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| WO-2006010008-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| CN-1492874-A | Macrolide antibiotics | — | 2004-04-28 | — | — | CN | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | HRH4 1045/4885CYP19A1 503/4885GUSB 2085/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | HRH4 1045/4885CYP19A1 503/4885GUSB 2085/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | HRH4 1500/4885CYP19A1 805/4885GUSB 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.